AU2019309242B2 - Imaging agents for radiolabeling exogenous and endogenous albumin - Google Patents

Imaging agents for radiolabeling exogenous and endogenous albumin Download PDF

Info

Publication number
AU2019309242B2
AU2019309242B2 AU2019309242A AU2019309242A AU2019309242B2 AU 2019309242 B2 AU2019309242 B2 AU 2019309242B2 AU 2019309242 A AU2019309242 A AU 2019309242A AU 2019309242 A AU2019309242 A AU 2019309242A AU 2019309242 B2 AU2019309242 B2 AU 2019309242B2
Authority
AU
Australia
Prior art keywords
metal complex
cancer
subject
albumin
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2019309242A
Other languages
English (en)
Other versions
AU2019309242A1 (en
Inventor
Khalid ABU AJAJ
Serghei CHERCHEJA
Steffen Daum
Javier Garcia Fernandez
Stephan David Koester
Felix Kratz
Johannes Pall MAGNUSSON
Federico Medda
Friederike I. Nollmann
Patricia PEREZ GALAN
Lara PES
Anna WARNECKE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LadRx Corp
Original Assignee
LadRx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LadRx Corp filed Critical LadRx Corp
Publication of AU2019309242A1 publication Critical patent/AU2019309242A1/en
Assigned to CYTRX CORPORATION reassignment CYTRX CORPORATION Request for Assignment Assignors: CENTURION BIOPHARMA CORPORATION
Assigned to LADRX CORPORATION reassignment LADRX CORPORATION Amend patent request/document other than specification (104) Assignors: CYTRX CORPORATION
Application granted granted Critical
Publication of AU2019309242B2 publication Critical patent/AU2019309242B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2019309242A 2018-07-23 2019-07-16 Imaging agents for radiolabeling exogenous and endogenous albumin Expired - Fee Related AU2019309242B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862702081P 2018-07-23 2018-07-23
US62/702,081 2018-07-23
PCT/US2019/042025 WO2020023247A1 (en) 2018-07-23 2019-07-16 Imaging agents for radiolabeling exogenous and endogenous albumin

Publications (2)

Publication Number Publication Date
AU2019309242A1 AU2019309242A1 (en) 2021-03-11
AU2019309242B2 true AU2019309242B2 (en) 2025-05-29

Family

ID=69181921

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019309242A Expired - Fee Related AU2019309242B2 (en) 2018-07-23 2019-07-16 Imaging agents for radiolabeling exogenous and endogenous albumin

Country Status (11)

Country Link
US (1) US20210353783A1 (https=)
EP (1) EP3826685A4 (https=)
JP (1) JP7395194B2 (https=)
KR (1) KR20210035213A (https=)
CN (1) CN112823028A (https=)
AU (1) AU2019309242B2 (https=)
BR (1) BR112021001314A2 (https=)
CA (1) CA3107328A1 (https=)
IL (1) IL280308B2 (https=)
MX (1) MX2021000926A (https=)
WO (1) WO2020023247A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3263646A1 (en) * 2022-07-29 2024-07-18 Curium Us Llc [177lu] lutetium-psma l&t composition, kit, method of making, and method of using thereof
AU2024317528A1 (en) 2023-07-31 2026-03-05 Curium Us Llc [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060251583A1 (en) * 2005-05-03 2006-11-09 Young-Don Hong DTPA derivatives and metal complexes thereof, and radiation source and contrast agent including the metal complexes
WO2008074960A2 (fr) * 2006-12-14 2008-06-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux conjugues, utilisables a des fins therapeutiques, et/ou a titre d'agent de diagnostic et/ou d'imagerie et leur procede de preparation
US20100056776A1 (en) * 2006-11-06 2010-03-04 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Method of preparing macromolecular contrast agents and uses thereof
US20120064002A1 (en) * 2003-02-04 2012-03-15 Lutz Lehmann Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents
US20160025713A1 (en) * 2002-09-12 2016-01-28 Life Technologies Corporation Site-specific labeling of affinity tags in fusion proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094950A (en) * 1988-06-07 1992-03-10 Nihon Medi-Physics Co., Ltd. Diethylenetriamine pentaacetic acid derivatives
DE10305463A1 (de) * 2003-02-04 2004-08-12 Schering Ag Enantiomerenreines (4S,8S)- und (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triza-3N,6N,9N-tricarboxymethyl-1,11-undecandisäure und deren Abkömmlinge, Verfahren zu deren Herstellung und Verwendung zur Herstellung pharmazeutischer Mittel
EP2630971B8 (en) * 2012-02-21 2017-12-13 Vergell Medical S.A. Combinations of albumin-based drug delivery systems

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160025713A1 (en) * 2002-09-12 2016-01-28 Life Technologies Corporation Site-specific labeling of affinity tags in fusion proteins
US20120064002A1 (en) * 2003-02-04 2012-03-15 Lutz Lehmann Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents
US20060251583A1 (en) * 2005-05-03 2006-11-09 Young-Don Hong DTPA derivatives and metal complexes thereof, and radiation source and contrast agent including the metal complexes
US20100056776A1 (en) * 2006-11-06 2010-03-04 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Method of preparing macromolecular contrast agents and uses thereof
WO2008074960A2 (fr) * 2006-12-14 2008-06-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux conjugues, utilisables a des fins therapeutiques, et/ou a titre d'agent de diagnostic et/ou d'imagerie et leur procede de preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOBAYASHI N. ET AL: "Toward in Vivo Imaging of Heart Disease Using a Radiolabeled Single-Chain Fv Fragment Targeting Tenascin-C", ANALYTICAL CHEMISTRY, 2011, vol 83, issue 23, pages 9123-9130, DOI: 10.1021/ac202159p *

Also Published As

Publication number Publication date
EP3826685A4 (en) 2022-04-06
MX2021000926A (es) 2021-03-31
JP2021532123A (ja) 2021-11-25
JP7395194B2 (ja) 2023-12-11
EP3826685A1 (en) 2021-06-02
WO2020023247A1 (en) 2020-01-30
IL280308B2 (en) 2024-09-01
KR20210035213A (ko) 2021-03-31
CN112823028A (zh) 2021-05-18
AU2019309242A1 (en) 2021-03-11
BR112021001314A2 (pt) 2021-05-11
US20210353783A1 (en) 2021-11-18
CA3107328A1 (en) 2020-01-30
IL280308A (en) 2021-03-01
IL280308B1 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
CA2950892C (en) Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
ES2675320T3 (es) Dendrímeros dirigidos a PSMA
CA3090812A1 (en) Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
ES2990974T3 (es) Conjugados de folato de entidades fijadoras de albúmina
US9217009B2 (en) Version of FDG detectable by single-photon emission computed tomography
US20250025582A1 (en) Ligands and their use
BR112021008480A2 (pt) dendrímeros, composição, métodos para determinar se um indivíduo tem um câncer, para determinar a progressão de um câncer, para determinar uma terapia apropriada para um indivíduo e para determinar a eficácia de uma terapia contra o câncer, métodos de imagem de um câncer em um indivíduo e de tratamento de câncer, usos de um dendrímero, intermediário para a produção de um dendrímero, kit e processo para a produção de um dendrímero
EP3197502A1 (en) Methods of treating cancer with tubulysin conjugates
AU2019309242B2 (en) Imaging agents for radiolabeling exogenous and endogenous albumin
US11191778B2 (en) Multifunctional linker technology containing an N4 group
CA2978304A1 (en) Methods of treating cancer with a psma ligand-tubulysin compound
RU2819907C2 (ru) Средства визуализации для меченного радиоактивным изотопом экзогенного и эндогенного альбумина
KR20260006628A (ko) 섬유아세포 활성화 단백질을 표적화하는 리간드
KR102040476B1 (ko) 촬상 및 치료를 위한 에틸렌디시스테인-당 콘쥬게이트의 효율적 합성법
WO2020045638A1 (ja) 放射性イミダゾチアジアゾール誘導体化合物
WO2025123118A1 (en) Radiolabeled fructose derivatives for medical imaging
WO2025163025A1 (en) Pyridophane macrocyclic ligands and fe(iii) complexes thereof
KR20250065366A (ko) 방사성핵종 조성물 및 이를 이용한 종양세포 검출 방법
JP2015063503A (ja) 放射性テクネチウムの結合部位を有する化合物、及び、その放射性テクネチウム錯体

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CYTRX CORPORATION

Free format text: FORMER APPLICANT(S): CENTURION BIOPHARMA CORPORATION

HB Alteration of name in register

Owner name: LADRX CORPORATION

Free format text: FORMER NAME(S): CYTRX CORPORATION

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application